Anti-cervical cancer effects of Compound Yangshe granule through the PI3K/AKT pathway based on network pharmacology

颗粒(地质) 药物数据库 小桶 药理学 体内 体外 医学 传统医学 生物 基因 药品 转录组 基因表达 生物化学 遗传学 古生物学
作者
Chao Ma,Yongwei Gu,Chang Liu,Xiaomeng Tang,Jianchao Yu,Dan Li,Jiyong Liu
出处
期刊:Journal of Ethnopharmacology [Elsevier BV]
卷期号:301: 115820-115820 被引量:17
标识
DOI:10.1016/j.jep.2022.115820
摘要

Compound Yangshe granule is a characteristic Chinese preparation against cervical cancer used at Fudan University Shanghai Cancer Center, and it consists of Hedyotis Diffusae Herba, Solani Lyrati Herba, Rubiae Radix et Rhizoma, Echinopsis Radix, Angelicae Sinensis Radix, Codonopsis Radix and Atractylodis Macrocephalae Rhizoma.The objective of the current study was to investigate the preclinical efficacy of compound Yangshe granule against cervical cancer and elucidate the underlying mechanisms.Antitumor effect of the preparation was investigated in U14 cells in vitro and subcutaneous xenograft mice in vivo. The underlying mechanisms were investigated by through network pharmacological analysis and identified by in vitro study. The components of compound Yangshe granule were collected from the Traditional Chinese Medicine Systems Pharmacology database, and the corresponding targets were predicted by the SwissTargetPrediction database. The targets involved in cervical cancer were collected from the GeneCards, Online Mendelian Inheritance in Man and DrugBank databases. A protein‒protein interaction network was constructed by using the String platform. The drug-disease-target network was plotted by Cytoscape software. Kyoto Encyclopedia of Genes and Genomes and Gene Ontology enrichment analyses were performed to investigate hub targets.After treatment with 0.5-10 mg/mL compound Yangshe granule, the survival rates of U14 cells gradually declined to 53.32% for 24 h, 23.62% for 48 h, and 12.81% for 72 h. The apoptosis rates of U14 cells gradually increased to 15.52% for 24 h, 23.87% for 48 h, and 65.01% for 72 h after treatment with 2-10 mg/mL compound Yangshe granule. After oral administration of compound Yangshe granule by xenograft mice, the tumor inhibition rates reached 52.27%, 74.62%, and 82.70% in the low, middle, and high dose groups, respectively. According to the network pharmacological analysis, quercetin, luteolin and naringenin were the most bioactive ingredients of the preparation. Kyoto Encyclopedia of Genes and Genomes pathway analysis showed that compound Yangshe granule may combat cervical cancer through the PI3K/AKT pathway.In summary, network pharmacology combined with biological experiments demonstrated that the main bioactive components including quercetin, luteolin and naringenin could inhibit the tumor growth by regulating the PI3K/AKT pathway and Bcl-2 family. Thus, compound Yangshe granule may be a promising adjuvant therapy for cervical cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
nana完成签到,获得积分10
刚刚
激动的八宝粥完成签到 ,获得积分10
1秒前
1秒前
科研通AI6应助落寞的易绿采纳,获得10
2秒前
善学以致用应助jerry采纳,获得10
3秒前
CHENXIN532完成签到,获得积分10
3秒前
爱笑小笼包完成签到,获得积分10
4秒前
修仙中应助行毅文采纳,获得10
6秒前
7秒前
7秒前
Optimistic发布了新的文献求助10
9秒前
烟花应助等待的谷波采纳,获得10
9秒前
9秒前
11秒前
Leon Lai发布了新的文献求助10
12秒前
13秒前
张梦宇发布了新的文献求助10
14秒前
15秒前
15秒前
Akim应助Fan采纳,获得10
16秒前
17秒前
18秒前
俊逸香岚完成签到,获得积分10
18秒前
良陈美景奈何天完成签到 ,获得积分10
19秒前
HughWang发布了新的文献求助10
20秒前
李爱国应助尊敬的雪珍采纳,获得10
20秒前
英吉利25发布了新的文献求助10
21秒前
jerry发布了新的文献求助10
21秒前
21秒前
邱小七发布了新的文献求助10
22秒前
22秒前
23秒前
tata0215完成签到 ,获得积分10
24秒前
laxy发布了新的文献求助20
24秒前
26秒前
TIPHA发布了新的文献求助10
27秒前
28秒前
bengbeng发布了新的文献求助10
28秒前
浮游应助范炎炎采纳,获得10
29秒前
29秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
LRZ Gitlab附件(3D Matching of TerraSAR-X Derived Ground Control Points to Mobile Mapping Data 附件) 2000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5133536
求助须知:如何正确求助?哪些是违规求助? 4334655
关于积分的说明 13504255
捐赠科研通 4171630
什么是DOI,文献DOI怎么找? 2287267
邀请新用户注册赠送积分活动 1288167
关于科研通互助平台的介绍 1229009